In-depth investigations into these mechanisms may pave the way for novel immune therapy strategies, such as combining DARS2 inhibitors with immune checkpoint inhibitors to improve the prognosis of BLCA patients. Here, DARS2 is linked to bladder transitional cell carcinoma.